Coenzym Q10

Zusammenfassung

Coenzym Q10 ist eine natürlich vorkommende, lipophile Verbindung bestehend aus einer ringförmigen Chinonstruktur, die in allen lebenden Zellen vorkommt. Es fungiert als ein wichtiger Cofaktor bei der Energiegewinnung innerhalb der Mitochondrien. Mit zunehmendem Alter und unter Einfluss einiger Medikamente nimmt die Coenzym-Q10-Konzentration im Körper ab, wobei diese Abnahme in den verschiedenen Organen unterschiedlich ausgeprägt ist. Die Abnahme der Coenzym-Q10-Konzentration der verschiedenen Organe könnte mit ein Grund für deren altersbedingten Funktionsverlust darstellen, dem durch eine Supplementation begegnet werden könnte. Ferner haben diverse Studien wiederholt gezeigt, dass eine Vielzahl von Krankheitsbildern - allen voran Herz-Kreislauf-Erkrankungen - gut auf eine Behandlung mit Coenzym Q10 ansprechen, und das ohne nennenswerte Nebenwirkungen. In wieweit sich Coenzym Q10 in der Therapie etablieren wird, bleibt abzuwarten.

Summary

Coenzyme Q10 is a lipophilic compound with an annular quinone structure widely distributed in all living cells. It functions as an important cofactor involved in the energy generation of mitochondria. As a person grows older and influenced by certain medicaments the coenzyme Q10 concentration in the body will decrease, varying with individual organs. This variation of the Q10 concentration in individual organs is considered to be the reason for their property to lose their efficacy with growing age, a fact that could be counteracted by supplementation. Moreover, several studies have come to the conclusion that a great number of diseases - primarily heart and circulatory disorders - will positively respond to a treatment with coenzyme Q10, even without significant side effects. It remains to be seen whether coenzyme Q10 will become a standard therapy.

Schlüsselwörter

Coenzym Q10 - Funktion - Supplementation - Herz-Kreislauf-Erkrankungen - Alter

Key words

Coenzyme Q10 - ubiquinones - function - supplementation - heart and circulatory diseases - age

Literatur

• 1 Folkers K, Langsjoen P, Willis R, Richardson P. et al. . Lovastatin decreases coenzyme Q levels in humans.  Proc Natl Acad Sci USA. 1990;  87 8931-8934
• 2 Folkers K, Osterborg A, Nylander M. et al. . Activities of vitamin Q10 in animal models and a serious deficiency in patients with cancer.  Biochem Biophys Res Comm. 1997;  234 296-299
• 3 Godsland IF, Stevenson JC. Insulin resistance: syndrome or tendency?.  Lancet. 1995;  346 100-103
• 4 Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome.  Am J Cardiol. 1999;  83 25-29
• 5 Hamada M, Kazatani Y, Ochi T, Ito T, Kokubu T. Correlation between serum CoQ10 level and myocardial contractility in hypertensive patients. Biomedical and Clinical Aspects of Coenzyme Q.  Amsterdam: Elsevier. 1984;  4 263-270
• 6 Jolliet P, Simon N, Barre J. et al. . Plasma coenzyme Q10 concentrations in breast cancer: prognosis and therapeutic consequences.  Int J Clin Pharmacol Ther. 1998;  36 506-509
• 7 Judy WV, Folkers K, Hall JH. Improved long-term survival in coenzyme Q10 treated congestive heart failure patients compared to conventionally treated patients.  In: Folkers K, Littarru GP, Yamagami T (eds.): Biomedical and Clinical Aspects of Coenzyme Q.  Amsterdam: Elsevier. 1991;  6 291-298
• 8 Judy WV. et al. . Regression of prostate cancer and plasma specific antigens (PSA) in patients on treatment with CoQ10.  First Conference of the International Coenzyme Q10 Association.. 1998; 
• 9 Kalen A, Appelkvist EL, Dallner G. Age-related changes in the lipid compositions of rat and human tissues.  Lipids. 1989;  24 579-584
• 10 Kostner GM, Gavish D, Leopold B. et al. . HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels.  Circulation. 1989;  80 1313-1319
• 11 Kotchen TA. Attenuation of hypertension by insulin-sensitizing agents.  Hypertension. 1996;  28 219-223
• 12 Kucharska J. Deficit of coenzyme Q in heart and liver mitochondria of rats with streptozotocin-induced diabetes.  Physiol Res. 2000;  49 411-418
• 13 Lockwood K, Moesgaard S, Folkers K. Partial and complete regression of breast cancer in patients in relation to dosage of coenzyme Q10.  Biochem Biophys Res Comm. 1994;  199 1504-1508
• 14 Lockwood K, Moesgaard S, Yamamoto T, Folkers K. Progress on therapy of breast cancer with vitamin Q10 and the regression of metastases.  Biochem Biophys Res Comm. 1995;  212 172-177
• 15 Ma A, Zhang W, Liu Z. Effect of protection and repair of injury of mitochondrial membrane-phospholipid on prognosis in patients with dilated cardiomyopathy.  Blood Press Suppl. 1996;  3 53-55
• 16 Mortensen SA, Vadhanavikit S, Baandrup U, Folkers K. Long-term coenzyme Q10 therapy: a major advance in the management of resistant myocardial failure.  Drugs Exp Clin Res. 1985;  11 581-593
• 17 Mortensen SA, Bouchelouche P, Muratsu K, Folkers K. Clinical decline and relapse of cardiac patients on coenzyme Q10 withdrawal.  In: Folkers K, Yamamura Y (eds.): Biomedical and Clinical Aspects of Coenzyme Q.  Amsterdam: Elsevier. 1986;  5 281-290
• 18 Mortensen SA, Vadhanavikit S, Muratsu K, Folkers K. Coenzyme Q10: clinical benefits with biochemical correlates suggesting a scientific breakthrough in the management of chronic heart failure.  Int J Tissue React. 1990;  12 155-162
• 19 Neuenschwander R, Burke BE, Olson RD. Randomized, double-blind, placebo-controlled trial of coenzyme.  South Med J. 2001;  94 1112-1117
• 20 Preuss HG. Effects of glucose/insulin perturbations on aging and chronic disorders of aging: the evidence.  J Am Coll Nutr. 1997;  16 397-403
• 21 Richardson P, Drzewoski J, Ellis J, Shizukuishi S. et al. . Reduction of elevated blood pressure by coenzyme Q10. Biomedical and Clinical Aspects of Coenzyme Q.  Amsterdam: Elsevier. 1981;  3 229-234
• 22 Singh RB, Wander GS, Rastogi A. et al. . Randomized, double-blind placebo-controlled trial of coenzyme Q10 in patients with acute myocardial infarction.  Cardiovasc Drugs Ther. 1998;  12 347-353
• 23 Singh RB, Niaz MA, Rastogi SS. et al. . Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease.  J Hum Hypertens. 1999;  13 203-208
• 24 Stetinova V. Effects of known and potential antioxidants on animal models of pathological processes (diabetes, gastric lesions, allergic bronchospasm).  Exp Toxicol Pathol. 2000;  52 473-479
• 25 Tsuyuasaki T, Noro C, Kikawada R. Mechanocardiography of ischemic or hypertensive heart disease.  In: Yamamura Y, Folkers K (eds.): Biomedical and Clinical Aspects of Coenzyme Q.  Amsterdam: Elsevier. 1980;  2 273-288
• 26 Yamagami T, Takagi M, Akagami H, Kubo H. et al. . Effect of coenzyme Q10 on essential hypertension, a double blind controlled study. Biomedical and Clinical Aspects of Coenzyme Q.  Amsterdam: Elsevier. 1986;  5 337-343